3SBio Inc. – Product Pipeline Review

Global Markets Direct’s, ‘3SBio Inc. – Product Pipeline Review – 2016’, provides an overview of the 3SBio Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by 3SBio Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of 3SBio Inc.

The report provides overview of 3SBio Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses 3SBio Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features 3SBio Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate 3SBio Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for 3SBio Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 3SBio Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

3SBio Inc. Snapshot 7

3SBio Inc. Overview 7

Key Information 7

Key Facts 7

3SBio Inc. - Research and Development Overview 8

Key Therapeutic Areas 8

3SBio Inc. - Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products - Monotherapy 12

Pipeline Products - Combination Treatment Modalities 13

Pipeline Products - Partnered Products 14

Partnered Products/Combination Treatment Modalities 15

3SBio Inc. - Pipeline Products Glance 16

3SBio Inc. - Late Stage Pipeline Products 16

Phase III Products/Combination Treatment Modalities 16

3SBio Inc. - Clinical Stage Pipeline Products 17

Phase II Products/Combination Treatment Modalities 17

Phase I Products/Combination Treatment Modalities 18

3SBio Inc. - Early Stage Pipeline Products 19

IND/CTA Filed Products/Combination Treatment Modalities 19

Preclinical Products/Combination Treatment Modalities 20

3SBio Inc. - Drug Profiles 21

(clindamycin phosphate + tretinoin) 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

AT-101 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

SSS-06 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

SSS-07 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

(tipiracil hydrochloride + trifluridine) 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

cinacalcet hydrochloride 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

colestilan chloride 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

eltrombopag olamine 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

nadroparin calcium 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

PEG-EPO 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

PEG-irinotecan 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

pegadricase 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

sevelamer carbonate 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

trelagliptin succinate 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

(betamethasone valerate + calcipotriene) 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

APG-1387 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

desonide 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

DJ-5 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

DNP-001 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

ferric citrate 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

fondaparinux sodium 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

PMC-001 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Small Molecule to Inhibit HIF-PH for Renal Anemia 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

SSS-08 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

thrombopoietin 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

TTAC-0001 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

3SBio Inc. - Pipeline Analysis 55

3SBio Inc. - Pipeline Products by Target 55

3SBio Inc. - Pipeline Products by Route of Administration 57

3SBio Inc. - Pipeline Products by Molecule Type 58

3SBio Inc. - Pipeline Products by Mechanism of Action 59

3SBio Inc. - Recent Pipeline Updates 61

3SBio Inc. - Dormant Projects 75

3SBio Inc. - Discontinued Pipeline Products 76

Discontinued Pipeline Product Profiles 76

NuLeusin 76

3SBio Inc. - Company Statement 77

3SBio Inc. - Locations And Subsidiaries 78

Head Office 78

Other Locations & Subsidiaries 78

Appendix 80

Methodology 80

Coverage 80

Secondary Research 80

Primary Research 80

Expert Panel Validation 80

Contact Us 80

Disclaimer 81

List of Tables

List of Tables

3SBio Inc., Key Information 7

3SBio Inc., Key Facts 7

3SBio Inc. – Pipeline by Indication, 2016 9

3SBio Inc. – Pipeline by Stage of Development, 2016 11

3SBio Inc. – Monotherapy Products in Pipeline, 2016 12

3SBio Inc. – Combination Treatment Modalities in Pipeline, 2016 13

3SBio Inc. – Partnered Products in Pipeline, 2016 14

3SBio Inc. – Partnered Products/ Combination Treatment Modalities, 2016 15

3SBio Inc. – Phase III, 2016 16

3SBio Inc. – Phase II, 2016 17

3SBio Inc. – Phase I, 2016 18

3SBio Inc. – IND/CTA Filed, 2016 19

3SBio Inc. – Preclinical, 2016 20

3SBio Inc. – Pipeline by Target, 2016 55

3SBio Inc. – Pipeline by Route of Administration, 2016 57

3SBio Inc. – Pipeline by Molecule Type, 2016 58

3SBio Inc. – Pipeline Products by Mechanism of Action, 2016 60

3SBio Inc. – Recent Pipeline Updates, 2016 61

3SBio Inc. – Dormant Developmental Projects,2016 75

3SBio Inc. – Discontinued Pipeline Products, 2016 76

3SBio Inc., Other Locations 78

3SBio Inc., Subsidiaries 79

List of Figures

List of Figures

3SBio Inc. – Pipeline by Top 10 Indication, 2016 9

3SBio Inc. – Pipeline by Stage of Development, 2016 11

3SBio Inc. – Monotherapy Products in Pipeline, 2016 12

3SBio Inc. – Combination Treatment Modalities in Pipeline, 2016 13

3SBio Inc. – Partnered Products in Pipeline, 2016 14

3SBio Inc. – Pipeline by Top 10 Target, 2016 55

3SBio Inc. – Pipeline by Route of Administration, 2016 57

3SBio Inc. – Pipeline by Molecule Type, 2016 58

3SBio Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 59

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports